[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456240":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":35,"centralContacts":40,"locations":50,"responsibleParty":69,"collaborators":44,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":44,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":44,"enrollmentInfo":82,"targetDuration":44,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":44,"overallStatus":52,"whyStopped":44,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Walter Reed National Military Medical Center","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaginal Estradiol with placebo oral pill","ACTIVE_COMPARATOR","Patient will receive 0.01% estradiol cream 1\u002F2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill",[13],"Drug: Vaginal estrogen",{"label":15,"type":10,"description":16,"interventionNames":17},"Oral Mirabegron with placebo vaginal cream","Patient will receive 50 milligrams oral Mirabegron once daily and placebo vaginal cream (Medisca's VersaPro Cream Base) once nightly for two weeks then three times per week",[18],"Drug: Mirabegron 50 MG [Myrbetriq]",[20,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Vaginal estrogen","0.01% estradiol cream 1\u002F2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill",[9],[26,27,28],"Estrace","Estradiol","Micronized Estrogen",{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Mirabegron 50 MG [Myrbetriq]","50mg oral Mirabegron once daily",[15],[34],"Myrbetriq",[36],{"name":37,"affiliation":38,"role":39},"Christopher W Heuer, DO","Urogynecology Fellow","PRINCIPAL_INVESTIGATOR",[41,46],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","2626231053",null,"christopher.w.heuer@gmail.com",{"name":47,"role":42,"phone":48,"phoneExt":44,"email":49},"Katherine L Dengler, MD","3522626861","katidengler12@gmail.com",[51],{"facility":5,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Bethesda","Maryland","20889","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-77.10026,38.98067,{"lat":62,"lon":61},[65],{"name":66,"role":42,"phone":67,"phoneExt":44,"email":68},"Deborah Kessler, RN, MSN","301-213-0143","deborah.d.kessler.civ@mail.mil",{"type":39,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Christopher W. Heuer, DO","Principal Investigator","100456240","phase-4-vaginal-estradiol-vs-oral-beta-3-agonist-for-overactive-bladder-syndrome-100456240",false,"NCT05221021","Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Raw score of 14 or more on OAB-q SF (adjusted score of 20)\n* Postmenopausal defined by not having a period for 12 months or bilateral oophorectomy a least 12 months status post procedure, or women with prior hysterectomy and preserved ovaries over age 55 years old or having a documented follicle stimulating hormone level greater than 40mIU\u002FmL.\n* Ability to speak and read English\n\nExclusion Criteria:\n\n* Contraindications to Vaginal Estrogen or Mirabegron\n* Post void residual \\>200mL or \\>1\u002F3 patient's total bladder volume\n* Currently on or previously taking anticholinergic or beta- 3 agonists within the past 1 month\n* Symptomatic pelvic organ prolapse greater than Stage 2, contraindication to vaginal estrogen therapy\n* Undiagnosed postmenopausal vaginal bleeding within the past 12 months\n* Current diagnosis of Multiple sclerosis, Parkinson's Disease, prior spinal cord injury, Spina Bifida, prior pelvic irradiation, Interstitial Cystitis, recurrent urinary tract infection.",true,"FEMALE","18 Years",{"count":83,"type":84},152,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.",[90],"Overactive Bladder Syndrome","2024-08-15",{"date":93,"type":94},"2024-08-19","ACTUAL",{"date":96,"type":94},"2022-10-01",{"date":98,"type":84},"2027-01-30",{"name":5,"class":6},1]